Gilead Sciences Inc (NASDAQ:GILD)

105.96
Data as of Sep 19
 +0.03 / +0.03%
Today’s Change
58.81
Today|||52-Week Range
110.64
+41.09%
Year-to-Date
VIVUS and Auxilium Announce Stendra Label Expansion - Analyst Blog
Sep 19 / Zacks.com
3 Huge Stocks on Traders' Radars
Sep 18 / TheStreet.com
Bristol-Myers' (BMY) Yervoy Label Expanded in Canada - Analyst Blog
Sep 19 / Zacks.com
Merck Posts Positive Data on Osteoporosis Drug Odanacatib - Analyst Blog
Sep 17 / Zacks.com
Bayer to Shed MaterialScience Business, Shares Rise - Analyst Blog
Sep 19 / Zacks.com
Shire's Vyvanse Accepted for FDA Review for Binge Eating - Analyst Blog
Sep 17 / Zacks.com
Spectrum Pharmaceuticals Out-Licenses Products in China - Analyst Blog
Sep 19 / Zacks.com
UCB-Amgen Reveals Positive Data on Romosozumab for PMO - Analyst Blog
Sep 17 / Zacks.com
Eli Lilly's Trulicity Approved by FDA for Type II Diabetes - Analyst Blog
Sep 19 / Zacks.com
Abbott Labs (ABT) to Initiate New Trial on Absorb - Analyst Blog
Sep 17 / Zacks.com
Is Merck KGaA on Track with its "Fit for 2018" Program? - Analyst Blog
Sep 19 / Zacks.com
AstraZeneca's Constipation Drug Movantik Gets FDA Nod - Analyst Blog
Sep 17 / Zacks.com
Notable Upgrades: Gilead Sciences (GILD), Ideal Power (IPWR), American Eagle Outfitte...
Sep 19 / Investing Channel
Regeneron Gets Breakthrough Therapy Status for Eylea - Analyst Blog
Sep 17 / Zacks.com
Dividend Aristocrats: Time to Buy AbbVie Inc Stock?
Sep 19 / MotleyFool.com
Biotech Stock Roundup: Avanir Soars on Phase II Data, Orexigen's Contrave Approved - ...
Sep 17 / Zacks.com
5 Things Gilead Sciences, Inc. Management Wants You to Know
Sep 19 / MotleyFool.com
Stock Market News for September 17, 2014 - Market News
Sep 17 / Zacks.com
Stock Market News for September 19, 2014 - Market News
Sep 19 / Zacks.com
This Top Growth Fund Leans Heavily On Large-Cap Tech
Sep 17 / Benzinga
VIVUS Inc. (VVUS) Rises: Stock Adds 12.4% in Session - Tale of the Tape
Sep 19 / Zacks.com
Fitz Bits: A Tightrope Walk
Sep 17 / TheStreet.com
US Stock Futures Signal Higher Start On Wall Street
Sep 19 / Benzinga
Roche Starts Trials on Lampalizumab for Geographic Atrophy - Analyst Blog
Sep 16 / Zacks.com
Sanofi & MyoKardia Ink Deal to Develop Cardiomyopathies - Analyst Blog
Sep 18 / Zacks.com
AstraZeneca and Eli Lilly Collaborate for Alzheimer's Drug - Analyst Blog
Sep 16 / Zacks.com
Bayer/Orion Progress with Prostate Cancer Drug ODM-201 - Analyst Blog
Sep 18 / Zacks.com
Synthetic Biologics' SYN-005 Gets Orphan Drug Designation - Analyst Blog
Sep 16 / Zacks.com
Alnylam (ALNY) to File Clinical Trial Application for ALN-CC5 - Analyst Blog
Sep 18 / Zacks.com
Gilead (GILD) Slips on Generic Sovaldi Licensing Deals - Analyst Blog
Sep 16 / Zacks.com
Gilead Down on Weak Simtuzumab Data and Sovaldi News - Analyst Blog
Sep 18 / Zacks.com
Stocks on the Move: Facebook (FB), Twitter (TWTR), Gilead Sciences (GILD), Microsoft ...
Sep 16 / Investing Channel
Rotating Into Blue Chips
Sep 18 / TheStreet.com
Is Illumina (ILMN) a Buy on Solid Q2, Strategic Road Map? - Analyst Blog
Sep 16 / Zacks.com
2 Columbia Growth Funds Notch Impressive Three-Month Performance
Sep 18 / Benzinga
The Best Biotech Stocks To Buy Now
Sep 16 / Investing Channel
Europe struggles to catch US biotech bulls
Sep 18 / FT.com
Stock Market News for September 16, 2014 - Market News
Sep 16 / Zacks.com
Is It Time to Buy Dividend Stock Bristol-Myers Squibb Co?
Sep 18 / MotleyFool.com
Deutsche Bank Is Bullish On Gilead Sciences, Inc. And Other Biotech Stocks
Sep 16 / Benzinga
ImmunoCellular Therapeutics (IMUC) Jumps: Stock Up 9% - Tale of the Tape
Sep 18 / Zacks.com
Benzinga's Top #PreMarket Losers
Sep 16 / Benzinga
Halozyme Therapeutics (HALO) Jumps: Stock Up 9.3% - Tale of the Tape
Sep 18 / Zacks.com
NPS Pharmaceuticals' Natpara Gets Positive FDA Panel Vote - Analyst Blog
Sep 15 / Zacks.com
Repros Therapeutics (RPRX) Crumbles: Stock Falls by 10.5% - Tale of the Tape
Sep 18 / Zacks.com
Alnylam Expands Pipeline with Preeclampsia Drug ALN-AGT - Analyst Blog
Sep 15 / Zacks.com
Gilead Sciences, inc. Stock's Incoming Game Changer
Sep 18 / MotleyFool.com
Biogen/AbbVie Report Positive Data on MS Drug Zinbryta - Analyst Blog
Sep 15 / Zacks.com
3 Best Stocks for Investing in Biotech
Sep 18 / MotleyFool.com
Novartis Presents Positive Data on Lucentis and Jetrea - Analyst Blog
Sep 15 / Zacks.com

To view my watchlist

Not a member yet?

Sign up now for a free account
Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer Morningstar: © 2014 Morningstar, Inc. All Rights Reserved. Disclaimer The Dow Jones IndexesSM are proprietary to and distributed by Dow Jones & Company, Inc. and have been licensed for use. All content of the Dow Jones IndexesSM © 2014 is proprietary to Dow Jones & Company, Inc. Chicago Mercantile Association. The market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. FactSet Research Systems Inc. 2014. All rights reserved. Most stock quote data provided by BATS.